Galileo – Biotech Innovation Fund BC USD

Reference Data

ISIN LU2226244361
Valor Number
Bloomberg Global ID
Fund Name Galileo – Biotech Innovation Fund BC USD
Fund Provider IPConcept (Luxemburg) S.A. Zürich, Switzerland
Phone: +352 260248-1
E-Mail: info.lu@ipconcept.com
Web: www.ipconcept.com
Fund Provider IPConcept (Luxemburg) S.A.
Representative in Switzerland IPConcept (Schweiz) AG
Zürich
Phone: +41 044 224 32 09
Distributor(s) Bellecapital AG
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition The fund charges a transaction fee (contribution towards expenses incurred in the investment of new assets)
Redemption Condition The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel)
Investment Strategy *** The objective of the investment policy for the sub-fund is to achieve an appropriate level of growth in the sub-fund currency while taking the investment risk into account. The sub-fund is actively managed. The composition of the portfolio is determined by the Fund Manager solely in accordance with the criteria laid down in the investment objectives / the investment policy, is regularly reviewed and, if necessary, adjusted. The sub-fund is not managed using an index as a benchmark.
Peculiarities

Fund Prices

Current Price * 43.02 USD 07.03.2025
Previous Price * 43.03 USD 06.03.2025
52 Week High * 74.84 USD 11.03.2024
52 Week Low * 41.53 USD 04.03.2025
NAV * 43.02 USD 07.03.2025
Issue Price * 43.02 USD 07.03.2025
Redemption Price * 43.02 USD 07.03.2025
Closing Price *
Indicative Minimum Price
Fund Assets *** 28,731,567
Unit/Share Assets *** 27,742,956
Trading Information SIX

Performance

YTD Performance -8.41% 30.12.2024
07.03.2025
YTD Performance (in CHF) -10.53% 30.12.2024
07.03.2025
1 month -7.52% 07.02.2025
07.03.2025
3 months -19.45% 09.12.2024
07.03.2025
6 months -21.24% 09.09.2024
07.03.2025
1 year -42.59% 07.03.2024
07.03.2025
2 years -32.31% 07.03.2023
07.03.2025
3 years -46.23% 07.03.2022
07.03.2025
5 years -71.32% 31.03.2021
07.03.2025

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Krystal Biotech Inc 9.81%
Arcellx Inc 8.73%
Alnylam Pharmaceuticals Inc 4.46%
Stoke Therapeutics Inc 3.73%
Iovance Biotherapeutics Inc 3.40%
Q32 Bio Inc 3.39%
Sarepta Therapeutics Inc 3.02%
Rocket Pharmaceuticals Inc 2.91%
Silence Therapeutics PLC ADR 2.85%
4D Molecular Therapeutics Inc Ordinary Shares 2.76%
Last data update 31.08.2024

Cost / Risk

TER
TER date
Performance Fee ***
PTR
Max. Management Fee ***
Ongoing Charges *** 0.44%
SRRI ***
SRRI date *** 28.02.2025

ESG Fund Ratings

Low Carbon Designation ***
ESG Rating Overall ***
ESG Rating Corporate ***
ESG Rating Sovereign ***
% AuM H&S Controversies ***

Breakdowns

Countries ***

Stock Sectors ***

Bond Sectors ***

ESG Carbon Metrics

Avg Carbon Risk Score ***
Avg Carbon Risk Cat Avg ***
% AuM Covered Carbon ***
Avg Fossil Fuel Exposure ***
Fossil Fuel Cat Avg ***

ESG Strategy

Strategy Level 1 ***
Strategy Level 2 ***
Strategy Level 3 ***
Exclusions Level 1 ***
Exclusions Level 2 ***

* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)